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Abstract
Background Ulcerative colitis (UC) is a Th2 inflammatory bowel disease characterized by increased IL-5 and IL-13 expression, eosinophilic/neutrophilic infiltration, decreased mucus production, impaired epithelial barrier, and bacterial dysbiosis of
the colon. Acetylcholine and nicotine stimulate mucus production and suppress Th2 inflammation through nicotinic receptors
in lungs but UC is rarely observed in smokers and the mechanism of the protection is unclear.
Methods In order to evaluate whether acetylcholine can ameliorate UC-associated pathologies, we employed a mouse
model of dextran sodium sulfate (DSS)-induced UC-like conditions, and a group of mice were treated with Pyridostigmine
bromide (PB) to increase acetylcholine availability. The effects on colonic tissue morphology, Th2 inflammatory factors,
MUC2 mucin, and gut microbiota were analyzed.
Results DSS challenge damaged the murine colonic architecture, reduced the MUC2 mucin and the tight-junction protein
ZO-1. The PB treatment significantly attenuated these DSS-induced responses along with the eosinophilic infiltration and
the pro-Th2 inflammatory factors. Moreover, PB inhibited the DSS-induced loss of commensal Clostridia and Flavobacteria,
and the gain of pathogenic Erysipelotrichia and Fusobacteria.
Conclusions Together, these data suggest that in colons of a murine model, PB promotes MUC2 synthesis, suppresses Th2
inflammation and attenuates bacterial dysbiosis therefore, PB has a therapeutic potential in UC.
Keywords Ulcerative colitis · Pyridostigmine bromide · Dextran sodium sulfate · Bacterial dysbiosis · Acetylcholine
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Introduction
Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disease (IBD), where inflammation is mainly
restricted to colon. The incidence of UC is steadily increasing particularly in the Western world [1]. Although the exact
etiology of UC is unclear, increasing evidence suggests that
a combination of factors including genetics, environmental
agents, immune dysregulation, gut barrier dysfunction, and
dysbiosis of the gut microbiota influence the course of the
disease [2, 3]. UC is rarely observed in smokers, as nicotine/nicotinic receptor agonists suppress colitis [4]; however,
the mechanism by which cigarette smoke/nicotine suppresses the development of UC is unclear. UC is primarily a
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Th2-mediated IBD associated with eosinophilic infiltration
and overproduction of Th2 chemokines/cytokines including
eotaxin (CCL11), IL-5, and IL-13 [5–7]. In animal models,
activation of pulmonary nicotinic acetylcholine receptors
(nAChRs) moderates eosinophilic infiltration through suppression of Th2 responses [8]. In mammals, acetylcholine
(ACh) is the only known biological ligand for nAChRs, and
increasing evidence suggests that ACh and PB—the latter
of which increases ACh by inhibiting acetylcholine esterase
(AChE)—tend to protect against tissue injury [9, 10]. We
and others have shown that nicotine, ACh, and the AChE
inhibitor neostigmine bromide (similar to PB) promote
mucus formation in human lung epithelial cells through
α7-nAChRs [11, 12]. MUC2, the predominant mucin in the
gut, plays a critical role in gut homeostasis, and MUC2deficient mice develop colitis spontaneously [13]; however,
unlike MUC5AC in bronchial epithelial cells [14], IL-13
does not always stimulate MUC2 [15]. UC also affects gut
microbiota and the integrity of the epithelial barrier in the
colon [2, 5, 6]; thus normal fecal microbial transplantation
is a promising treatment for UC [16, 17]. As DSS has been
found to induce UC-like conditions in a mouse model [18,
19], in this study we examined whether PB attenuated DSSinduced colon pathology in C57BL/6 mice.

Materials and Methods
Animals
Pathogen-free 5–6-week-old C57BL/6 mice were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA). Animals were kept in chambers as described previously [11]. All
animal protocols were approved by the Institutional Animal
Care and Use Committee.

DSS and PB Treatment
Mice (8–9 weeks old) were divided into three groups (control, DSS, and DSS+PB) with 6–8 animals/group. PB and
DSS were purchased from Sigma-Aldrich, USA. Mice were
given PB through intraperitoneally implanted Alzet miniosmotic pumps [20] starting at day 7 prior to DSS treatment
and continued until they were euthanized. Mice implanted
with mini-osmotic pumps containing sterile saline served
as the control. The pumps provided PB at a concentration
of 2 mg/day/kg body weight. Colitis was induced by 3.0%
(w/v) DSS-containing water. The treatment continued for
7 days; the animals were euthanized and colons harvested
on day 8. Animals were weighed daily after DSS treatment.
Where indicated, intestines were dissected to obtain ileum,
cecum, and colon; tissues were frozen for RNA and protein,
and fecal material for bacterial microbiome analysis.
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Histochemical Staining and Scoring
Formalin-fixed and paraffin-embedded tissue sections (5
μm) were stained with hematoxylin and eosin (H&E) for
general histology. Histochemical staining with Alcian Blue
and periodic acid–Schiff reagent (AB–PAS) was carried out
as described previously [21]. Eosinophils and goblet cells
were enumerated microscopically. Tissue sections were
coded and assessed in a blinded manner. Histological damage was scored as described previously [18]. Briefly, sections were scored for eosinophil infiltration (0–3), with 0
representing less than three eosinophils per field of view at
40× magnification in the lamina propria, 1 for greater than
three eosinophils per field of view in the lamina propria, 2
representing confluence of eosinophils extending into the
submucosa, and 3 representing confluence of eosinophils
present in all tissue layers.

Immunofluorescence Imaging
Deparaffinized and hydrated tissue sections were washed in
0.05% v Brij-35 in phosphate-buffered saline (PBS; pH 7.4)
and immunostained for antigen expression as described previously [22]. Briefly, the antigens were unmasked and incubated in a blocking solution. The sections were stained with
antibodies to ZO-1 (Invitrogen Inc., Carlsbad, CA, USA) or
anti-eosinophil antibody (Novus Biologicals, Littleton, CO,
USA), or isotype control antibodies. Immunofluorescence
images were captured with a BZX700 all-in-one microscope
(Keyence Corp., Japan).

qRT‑PCR Analysis
Total RNA from frozen mouse colon tissue was isolated
using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH, USA). Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed using the
StepOnePlus detection system (Applied Biosystems, Foster
City, CA, USA) and the TaqMan One-Step RT-PCR kit containing AmpliTaq Gold® DNA polymerase [23]. Specific
primers and probes were obtained from Applied Biosystems.
Fold changes in qPCR expression were calculated by the
2(−ΔΔCT) method [24].

Western Blot Analysis
Western blot analysis of eotaxin, IL-5, IL-13 and MUC2
in mice colon homogenates was performed as described
previously [23]. Briefly, colon homogenates (70 μg) were
fractionated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for eotaxin, IL-5,
and IL-13, and 5% SDS-PAGE for MUC2. After transfer to

Digestive Diseases and Sciences (2020) 65:141–149

nitrocellulose membranes, blots were probed with antibodies to eotaxin, IL-5, IL-13, and MUC2 (Abcam), and after
stripping were re-probed with anti–β actin antibody.

Histological Grading
The H&E-stained sections were analyzed for histological grading to evaluate the severity of inflammation. The
total score ranged from 0 to 14, representing the sum of
scores from the following: (1) severity of inflammation, with
0 = none, 1 = mild, 2 = moderate, and 3 = severe; (2) mucosal
damage, with 0 = none, 1 = mucosal layer, 2 = submucosa, and 3 = transmural; (3) crypt damage, with 0 = none,
1 = basal one-third damage, 2 = basal two-thirds damage,
3 = crypt lost with intact epithelium, and 4 = crypt and epithelium lost; and (4) percentage involvement, with 0 = none,
1 = ≤25%, 2 = 26–50%, 3 = 51–75%, and 4 = 76–100%, as
previously described [25].

Bacterial Microbiome Analysis: Sequencing and 16S
DNA Analysis
Fecal contents were collected from the gut encompassing
distal cecum and distal sigmoid colon and frozen on dry ice.
The fecal matter was lysed using glass beads in a MagNA
Lyser tissue disruptor (Roche Diagnostics, Indianapolis,
IN, USA) and total DNA was isolated using the DNeasy
Powersoil® or AllPrep PowerFecal® DNA isolation kits
(MO BIO Laboratories, Carlsbad, CA, USA) and quantified
as described elsewhere [26]. Briefly, the bacterial 16S V4
rDNA region was amplified using fusion primers, and each
sample was PCR-amplified with two differently barcoded V4
fusion primers and loaded into the MiSeq cartridge (Illumina
Inc., San Diego, CA, USA). The amplicons were sequenced
for 250 cycles with custom primers designed for paired-end
sequencing. Using the QIIME platform, sequences were
quality-filtered and demultiplexed using exact matches to
the supplied DNA barcodes. The sequences were searched
against the Greengenes reference database and clustered at
97% by UCLUST (closed-reference operational taxonomic
unit [OTU] picking). The relative abundance of OTUs constituting a single phylum in treated animals was normalized
with the OTUs in controls. The resulting ratios were analyzed using Prism software (GraphPad Software, LA Jolla,
CA, USA) to identify changes between groups in the five
major bacterial phyla in the microbiome.
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Results and Discussion
PB Ameliorates the DSS‑Induced Increase in IL‑5
and Eotaxin
While the exact pathophysiology of UC is unknown, several
immune cell types, including neutrophils, eosinophils, and
lymphocytes, have been implicated in the disease process
[27, 28]. Similar to allergic asthma in the lungs, UC is a Th2
disease where eosinophils and eosinophil-associated proteins play a significant role in the disease pathology [29],
and eosinophilic granulocyte infiltration is seen in UC-associated inflammation [5, 30] and implicated in the pathophysiology of UC in humans [31, 32]. Moreover, eosinophils are
a therapeutic target for gut inflammation [33]. IL-5 drives
the growth of eosinophils, and eotaxin is the most potent
chemokine that stimulates eosinophilic infiltration, while
IL-13 affects the gut epithelial barrier; these factors are elevated in UC [27, 32], and interestingly, eosinophilic granules contain IL-5, IL-13, and eotaxin [34, 35]. Eotaxin has
been established as the chemokine that drives eosinophilic
infiltration in UC. We analyzed colonic tissues from control,
DSS-treated, and DSS+PB-treated mice for eosinophil infiltration of the tissue. Eosinophils were visualized by immunohistochemistry using an eosinophil-specific antibody that
showed that DSS stimulated eosinophilic infiltration of the
colon (Fig. 1a, left panel), with a pathology score of > 3.0,
which was significantly reduced by PB treatment (Fig. 1a,
right panel), indicating that inhibition of AChE partially protects the colon from infiltration by eosinophils. Accumulation of eosinophils at the site of inflammation requires cooperation between IL-5 and eotaxin [36], where IL-5 promotes
proliferation and differentiation of eosinophils, and eotaxin
is a potent chemoattractant for eosinophils that is increased
significantly in UC [5, 32, 33]. We determined the expression of IL-5 and eotaxin by Western blot and/or RT-qPCR
analyses. The results showed that DSS doubled the amount
of IL-5 protein in the colon, which was significantly reduced
by the PB treatment (Fig. 1b). DSS-induced IL-5 levels were
comparable to IL-5 mRNA levels observed in rectal biopsy
samples from UC patients [5]. Similarly, PB reduced eotaxin
protein (Fig. 1c) and eotaxin mRNA (Fig. 1d) levels. DSS
treatment has also been found to cause body weight loss
in mice [4]. Following DSS treatment, we weighed mice
daily. On day 4, DSS-treated animals began to exhibit loss
of body weight, and the decrease was statistically significant compared with control mice on day 5. However, on
day 5 there was no significant difference in body weight
between the control and DSS+PB groups (Fig. 1E). This
difference in body weight became significant on day 7/8, but
the reduction was lower than in the animals treated with DSS
alone ((Fig. 1e). These results suggest that PB slightly but
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Fig. 1  PB ameliorates the DSS-induced eosinophilic infiltration and
increased expression of IL-5 and eotaxin in the colon, and the reduction in body weight. a Colonic tissues from mice treated with DSS
alone or PB+DSS were analyzed for eosinophils on H&E-stained
sections and were compared with controls (magnification 400×). b
Western blot analysis of IL-5 in colonic homogenates (70 µg). Blots
were probed for IL-5 and β-actin levels and quantitated as the ratio
of IL-5/β-actin following densitometric analysis. c Eotaxin expression
by Western blots of colonic homogenates (70 µg) (left panel), den-

sitometric quantitation of eotaxin (right panel). d RT-qPCR analysis
of eotaxin mRNA expression in total colonic RNA. e PB effects on
DSS-induced body weight reduction on day 8 after DSS treatment.
Groups are as follows: Control (Cont), DSS: dextran sodium sulfatetreated, and DSS+PB: DSS and pyridostigmine bromide-treated. Figures are representative of two separate experiments (n = 4–5/group)
for A, B, C, and D and one experiment for E (n = 6–8 animals).
*≤ 0.01; **≤ 0.001; ***≤ 0.0001

Fig. 2  PB suppresses DSS-induced IL-13 expression and induces
MUC2 expression. a WB analysis of IL-13 in colonic homogenates
(70 µg). The blots were probed with anti-IL-13-specific antibody. The
bar graph represents quantitation by densitometry (ratio of IL-13/βactin). b Analysis of MUC2 expression by WB analysis of colon tis-

sue homogenates (70 µg) probed with MUC2-specific antibody. The
bar graph is quantitation of MUC2 by densitometry (ratio MUC2/
β-actin). Figures are representative of two separate experiments
(n = 4–5/group); where *≤ 0.01, **≤ 0.001, and ***≤ 0.0001

significantly moderates DSS-induced weight loss in mice.
Thus, PB appears to attenuate the pro-eosinophilic effects
of DSS in the mouse colon through downregulation of IL-5
and eotaxin expression and moderates the DSS-induced loss
of body weight.

[6, 37], which in excessive concentrations impairs the
integrity of colonic epithelium [38–40]. In the lung,
IL-13 induces airway mucin (MUC5AC) formation [11];
however, unlike the lung, IL-13 does not regulate mucin
(MUC2) production in the intestinal epithelial cells [41].
The lamina propria of UC patients produces substantially
more IL-13 than normal individuals [28, 42] and neutralization of IL-13 prevents experimental UC and attenuates
human UC [37, 43]. Therefore, we analyzed the effects
of PB on the IL-13 expression in gut tissues. Western
blot analysis indicated that DSS upregulates the expression of IL-13 protein and PB significantly downregulates

PB Inhibits DSS‑Induced IL‑13 Expression
and Improves Colonic Epithelial Integrity and MUC2
Mucin Expression
UC is predominantly a Th2 inflammatory disease and
IL-13 is the key effector cytokine in UC pathogenesis
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Fig. 3  PB ameliorates the colonic epithelial integrity loss and inflammation. a Representative H&E stained colon sections and the histological scoring of pathological severity. The lower panel shows
the enlarged images of the inset drawn on upper panels (scale, 50
microns). b Representative colonic expression of ZO-1 as assessed
by immunofluorescence analysis. Images show ZO-1 (in green)

and DAPI-stained nuclei (in blue). Lower panels show the enlarged
images of the inset drawn on upper panels. Image magnification
100× for upper panel and 400× for lower panel. Figures are representative of two separate experiments (n = 4–5/group); where *≤ 0.01,
**≤ 0.001, and ***≤ 0.0001

this response (Fig. 2a). The intestinal barrier consists of
epithelial columnar cells connected by intracellular junctions that are covered by mucus. The epithelium and the
mucus layer inhibit the invasion of gut mucosa by luminal
microbes. Impaired colonic barrier promotes gut inflammation and the thickness of the mucus layer is decreased
in active UC patients [44, 45]. Mucus is made by goblet cells, and the major gel-forming mucin in the gut is
MUC2 [46]. MUC2 synthesis is defective in UC patients,
and variants of MUC2 gene are associated with increased
incidence of UC [47]. In UC patients and experimental
animals, bacteria penetrate the normally impenetrable
colonic mucus layer and MUC2 expression is strongly
downregulated in UC [48]. MUC2 provides protection against colitis, and MUC2-deficient mice exhibit
increased susceptibility to colitis [49, 50]. We compared
the expression of MUC2 protein in DSS and DSS+PB
colons by Western blot analysis. The results presented
in Fig. 2B show that compared to normal colonic tissues, MUC2 protein expression is significantly decreased
(p < 0.05) by DSS; however, PB treatment strongly upregulates the expression of MUC2 protein in DSS-treated
animals (p < 0.01), and MUC2 expression is even higher
(p < 0.05) than the control group. These results suggest
that loss of MUC2 protein expression is associated with
UC inflammation, and PB promotes MUC2 expression.
Normal functioning of the gut epithelium requires tight
junction (TJ) proteins, which provide structural integrity
to the tissue by forming a highly polarized barrier with
selective paracellular permeability [51]. Histopathologically, UC is associated with disruption of TJ proteins and
the TJs are composed of proteins that include occludin,
claudins, junctional adhesion molecules, and intracellular scaffold proteins such as zonula occludens (ZO),
including ZO-1 [52]. ZO-1 is a scaffolding linker protein that interacts with occludin and is reduced in UC
patients [53]. To determine the effects of PB on colonic

architecture, colon tissues were stained with H&E and
analyzed for histological grading to evaluate the severity
of UC. We based the disease severity primarily on histopathological changes in the colon on a scale of 0–14 (see
“Materials and methods” section). As assessed by these
criteria, Fig. 3a shows that DSS-induced disease severity of 6.33 ± 0.42, which was significantly moderated by
PB to 2.67 ± 0.33. Moreover, as seen by immunofluorescence/immunohistochemistry analysis, the DSS-induced
reduction in colonic ZO-1 was attenuated by PB treatment
(Fig. 3b, in green). These results suggest that PB partially
protected mice from DSS-induced disruption of the gut
epithelial architecture.

PB Attenuates DSS‑Induced Dysbiosis of Microbiota
in the Colon
The intestines, particularly the colon, are inhabited by a large
number of microorganisms that normally provide symbiotic benefits to the host; however, barrier dysfunction in UC
causes unfavorable changes in the composition of gut microbiota (dysbiosis) that facilitates the penetration of colonic
mucus layers by these bacteria to induce gut inflammation
[13, 38, 54]. Normal gut bacterial microbial community
is typically dominated (nearly 95%) by phyla Firmicutes,
Bacteroidetes, and Proteobacteria [55], and each phylum
has members that are beneficial or pathogenic in the gut.
Imbalances in gut microbiota are seen in the DSS-induced
UC in mice [56], and recent results suggest that fecal transplants containing normal bacterial microbiota attenuate UC
symptoms in patients [17, 57] and in experimental animal
models [58].
To determine whether DSS-induced changes in the bacterial composition of the colon are attenuated by PB, we
analyzed the colonic 16S V4-rDNA. Figure 4a shows that in
a normal mouse colon (CON), Erysipelotrichia, Clostridia,
Flavobacteria, and Fusobacteria represent approximately

13

146

Digestive Diseases and Sciences (2020) 65:141–149

Fig. 4  PB attenuates DSS-induced dysbiosis of microbiota in the
colon. a Colonic 16S V4-rDNA from various groups was analyzed
for sequences specific for Erysipelotrichia, Clostridia, Flavobacteria and Fusobacteria. b The weighted Unifrac principal coordinate
analysis of the three groups. Microbiome from the control animals
is seen to cluster distinctly compared to DSS-treated animals. The
PB+DSS group is seen to cluster with the control group. p-value is

0.01 (control vs. DSS), 0.038 (DSS vs. PB+DSS) and 0.2 (control vs.
PB+DSS). Test of significance was a two-sided Student two-sample
t test, and non-parametric p-values (exact) were calculated using 999
Monte Carlo permutations. The figure presents the mean distribution
of the bacterial types (n = 4–5 colons/group) and is representative of
two separate experiments

69%, 14%, 13%, and 4% of all sequences, respectively, and
DSS treatment alters this composition to 82%, 3%, 7%, and
8%, respectively. Thus, DSS increases Erysipelotrichia and
Fusobacteria and decreases Clostridia and Fusobacteria in
the gut. PB treatment nearly restored the normal microbiota
composition of Erysipelotrichia, Clostridia, Flavobacteria,
and Fusobacteria to about 73%, 12%, 11% and 4%, respectively. The weighted Unifrac principal coordinate analysis
of the microbiome data shows that the microbiome from
the control animals cluster distinctly compared to the DSStreated animals (Fig. 4b).
Clostridia difficile infection is known to recur in UC
patients and is associated with increased morbidity and
mortality in this population [59]; however, organisms within
Clostridia genera are higher in normal gut flora and normal
fecal microbiota is used to treat recurrent Clostridia difficile
infection [60]. Both Clostridia and Erysipelotrichia belong
to phylum Firmicutes, but commensal Clostridia maintains
gut homeostasis and moderates Clostridia difficile infection
[60, 61]. Commensal Clostridia promotes the development
of anti-inflammatory IL-10-producing Fox3p+ T-reg cells in
the gut [62–64], and defects in the IL-10 or IL-10 receptor
are known to promote early onset of UC [65]. On the other
hand, Erysipelotrichia increases mucosal permeability and
stimulates inflammatory immune responses in the gut [66].
The role of Flavobacteria in the human gut has not been
clearly defined; however, Flavobacteria are less abundant
in human IBD [67]. Similarly, the function of Fusobacteria in the gut are unknown, but their numbers increase in

colorectal cancer [68], and UC increases susceptibility to
colon cancer [69]. Therefore, it is likely that PB, through
increased acetylcholine levels, (a) increases mucus formation and (b) inhibits the DSS-induced loss of the epithelial
barrier function by suppressing IL-13 production. Together,
this inhibits the DSS-induced migration of pathogenic bacteria and bacterial dysbiosis in the gut. Thus, PB has the
potential to stabilize gut flora and attenuate inflammation
associated with UC.
Cholinergic stimuli involving ACh are important in the
regulation of gut function, and ACh regulates both motility
and mucosal responses in the gut. Recent evidence suggests
that ACh and PB tend to be protective against experimental
tissue injury. PB restored cardiac autonomic balance in mice
and rats after experimental myocardial infarction [9, 70, 71],
and heart-specific overexpression of the ACh-synthesizing
enzyme choline acetyltransferase was found to protect the
myocardium against ischemia-induced injury in mice [72].
PB has also been shown to help some patients with spinal
cord injuries [73] and diabetic patients with gastrointestinal
disorders [74]. Moreover, release of ACh through electrical
stimulation of the vagus nerve ameliorates gut inflammation
through nAChRs [75]. We have shown that ACh and neostigmine bromide induce mucus production in airway epithelial cells through α7-nAChRs [11], and nicotine suppresses
both inflammatory and adaptive immune responses [76, 77];
interestingly, tobacco smokers were found to be very resistant to UC [78]. In mammals, ACh is the only known biological ligand that reacts with nicotinic as well as muscarinic
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receptors, and nAChRs on non-neuronal cells respond to
very low concentrations of nicotine [11, 79]. Therefore, it
is likely that at lower concentrations, ACh reacts primarily
with nAChRs thereby protecting the gut from colitis and
bacterial dysbiosis and has the potential to suppress UC.
Because nAChRs are present on many different cell types,
including T cells, monocytes/macrophages, and epithelial
cells, at present the identity of the cell type(s) that is/are the
primary target of acetylcholine in the gut is unclear. In the
lung, bronchial epithelial cells express nAChRs, and acetylcholine, neostigmine bromide, and nicotine promote mucus
production from these cells [11, 80]; however, nicotine is
known to inhibit Th2 immune responses through its effects
on T cells and macrophages [8, 81]. It is therefore likely that
the effects of acetylcholine/PB on UC severity involve multiple cell types. Further experiments are needed to identify
the target cell type(s) that is/are critical in moderating UC
in this model.
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